Product from the California Institute of Technology is based on a family of diverse variants of bacterial cytochrome P450 enzymes.
Codexis licensed intellectual property from the California Institute of Technology for preparing and identifying drug metabolites. The company plans to incorporate this technology in the development of new R&D productivity tools.
The licensed technology is based on development of a family of diverse variants of bacterial cytochrome P450 enzymes. “This enzyme family can facilitate identification of safer, more efficacious drugs earlier in the drug development process by expediting the production of potential human metabolites of drug candidates,” explains Peter Seufer-Wasserthal, Ph.D., vp and general manager, Codexis Pharma Services Group.
“Additionally, this technology can be used for lead diversification and complements the human cytochrome biocatalyst products and services at BioCatalytics, acquired by Codexis in July,” Dr. Seufer-Wasserthal remarked.